Keri Enns, APRN
Payments from drug & device makers
Across 207 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$793
- AbbVie$451
- Novo Nordisk$362
- Lilly USA, LLC$333
- GSK$319
- Boehringer Ingelheim$264
- plus $778 from 15 others
What the payments were for
- Food & beverage$3,299100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $793 |
| AbbVie | 41 | $451 |
| Novo Nordisk | 24 | $362 |
| Lilly USA, LLC | 21 | $333 |
| GSK | 24 | $319 |
| Boehringer Ingelheim | 15 | $264 |
| Pfizer | 10 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| Exact Sciences | 4 | $69 |
| Astellas Pharma US Inc | 2 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $57 |
| Bayer | 3 | $47 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Mylan Specialty L.p. | 1 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Dexcom, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
How this compares
$3,299 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $48,696 |
| JardianceEmpagliflozin | 41 | $34,510 |
| TrulicityDulaglutide | 15 | $28,445 |
| EliquisApixaban | 38 | $26,348 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,188 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $16,204 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,994 |
| FarxigaDapagliflozin Propanediol | 12 | $14,605 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $11,709 |
| XareltoRivaroxaban | 11 | $9,289 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $6,601 |
| Atorvastatin Calcium | 225 | $2,451 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,508 |
| Losartan Potassium | 114 | $1,338 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $1,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $264 | $50,71459 claims |
| Novo NordiskOzempic | $362 | $48,69626 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $793 | $30,59937 claims |
| Lilly USA, LLCTrulicity | $333 | $28,44515 claims |
| PfizerEliquis | $175 | $26,34838 claims |
| GSKTrelegy Ellipta | $319 | $21,18833 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $15 | $12,87129 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $41770 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.
Other family in Tulsa
- Candy WilliamsTulsa$22K
- Jillian OakleafTulsa$15K
- Lee MatlockTulsa$15K
- Vanessa ZickefooseTulsa$13K
- Erin RowanTulsa$13K
- Lora HortonTulsa$12K
- Darla NorrisTulsa$11K
- Cristina BarnesTulsa$11K
- Ashley RiouseTulsa$10K
- Jaclyn DrassTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.